Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD).
Venkatraman Radhakrishnan, Prasanth Srinivasan, Gargi Das et al.
✦ AI-curated · Sources linked
In 30 seconds
The CIVIC POD trial evaluated the efficacy of olanzapine versus dexamethasone for preventing chemotherapy-induced nausea and vomiting in children aged 4-18 receiving highly emetogenic chemotherapy. This multicenter, phase III, randomized noninferiority trial found that olanzapine achieved a complete response to vomiting of 63.5%, compared to 56.9% with dexamethasone, meeting noninferiority criteria with an absolute difference of 6.6%.
Key findings
- Complete response to vomiting was 63.5% with olanzapine versus 56.9% with dexamethasone.
- Acute-period complete response rates were 68.9% for olanzapine and 64.2% for dexamethasone.
- Any-grade somnolence occurred in 50.7% of patients receiving olanzapine compared to 17.2% with dexamethasone.
Why it matters
This study suggests that olanzapine can effectively manage chemotherapy-induced nausea and vomiting in pediatric patients without the use of dexamethasone, potentially reducing associated toxicities. Clinicians may consider this alternative to improve patient care.